Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Hepion Pharmaceuticals price target lowered to $8 from $14 at Roth Capital » 07:52
12/01/20
12/01
07:52
12/01/20
07:52
HEPA

Hepion Pharmaceuticals

$1.66 /

-0.03 (-1.78%)

Roth Capital analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
HEPA Hepion Pharmaceuticals
$1.66 /

-0.03 (-1.78%)

HEPA Hepion Pharmaceuticals
$1.66 /

-0.03 (-1.78%)

07/20/20 Roth Capital
Hepion Pharmaceuticals transferred with a Buy rating at Roth Capital
03/20/20 Roth Capital
Roth Capital says Hepion's CRV431 could be used in COVID-19 treatment
  • 25
    Nov
HEPA Hepion Pharmaceuticals
$1.66 /

-0.03 (-1.78%)

HEPA Hepion Pharmaceuticals
$1.66 /

-0.03 (-1.78%)

Recommendations
Apellis price target raised to $66 from $57 at BMO Capital » 06:51
12/01/20
12/01
06:51
12/01/20
06:51
APLS

Apellis

$47.14 /

-0.09 (-0.19%)

BMO Capital analyst…

BMO Capital analyst Matthew Luchini raised the firm's price target on Apellis to $66 from $57 and keeps an Outperform rating on the shares. The analyst is citing his proprietary survey data which indicates "strong enthusiasm" for the company's pegcetacoplan in PNH, or Paroxysmal Nocturnal Hemoglobinuria. Luchini adds that "pegcetacoplan should see rapid uptake", driven by treatment-experienced patients with a high transfusion burden or anemia.

ShowHide Related Items >><<
APLS Apellis
$47.14 /

-0.09 (-0.19%)

APLS Apellis
$47.14 /

-0.09 (-0.19%)

11/23/20 Citi
Apellis price target raised to $67 from $53 at Citi
11/19/20 Needham
Apellis initiated with a Buy at Needham
09/01/20
Fly Intel: Top five analyst initiations
08/31/20 Stifel
Apellis initiated with a Buy at Stifel
APLS Apellis
$47.14 /

-0.09 (-0.19%)

  • 09
    Jan
Friday
Conference/Events
Cantor Fitzgerald pharmaceuticals analysts hold analyst/industry conference call » 15:22
11/27/20
11/27
15:22
11/27/20
15:22
DRRX

Durect

$1.82 /

-0.045 (-2.41%)

Pharmaceuticals &…

Pharmaceuticals & Healthcare Analysts discuss DURECT Corporation's DUR-928 and the Alcoholic Hepatitis Landscape on an Analyst/Industry conference call to be held on December 9 at 10 am.

ShowHide Related Items >><<
DRRX Durect
$1.82 /

-0.045 (-2.41%)

DRRX Durect
$1.82 /

-0.045 (-2.41%)

11/23/20 Chardan
Durect positioned for 'market dominance' in alcoholic hepatitis, says Chardan
11/03/20 Chardan
Durect Covid trial update increased interest in program, says Chardan
10/30/20
Fly Intel: Top five analyst initiations
10/30/20 Chardan
Durect initiated with a Buy at Chardan
DRRX Durect
$1.82 /

-0.045 (-2.41%)

DRRX Durect
$1.82 /

-0.045 (-2.41%)

DRRX Durect
$1.82 /

-0.045 (-2.41%)

Over a week ago
Syndicate
Hepion Pharmaceuticals 20M share Spot Secondary priced at $1.50 » 19:35
11/24/20
11/24
19:35
11/24/20
19:35
HEPA

Hepion Pharmaceuticals

$2.18 /

-0.185 (-7.82%)

The deal priced below the…

The deal priced below the last closing price of $2.18. ThinkEquity is acting as sole book running manager for the offering.

ShowHide Related Items >><<
HEPA Hepion Pharmaceuticals
$2.18 /

-0.185 (-7.82%)

HEPA Hepion Pharmaceuticals
$2.18 /

-0.185 (-7.82%)

07/20/20 Roth Capital
Hepion Pharmaceuticals transferred with a Buy rating at Roth Capital
03/20/20 Roth Capital
Roth Capital says Hepion's CRV431 could be used in COVID-19 treatment
HEPA Hepion Pharmaceuticals
$2.18 /

-0.185 (-7.82%)

HEPA Hepion Pharmaceuticals
$2.18 /

-0.185 (-7.82%)

Conference/Events
Immunic management to meet virtually with Mizuho » 04:55
11/24/20
11/24
04:55
11/24/20
04:55
IMUX

Immunic

$19.96 /

+1.14 (+6.06%)

Virtual Meeting to be…

Virtual Meeting to be held on November 24 hosted by Mizuho.

ShowHide Related Items >><<
IMUX Immunic
$19.96 /

+1.14 (+6.06%)

IMUX Immunic
$19.96 /

+1.14 (+6.06%)

11/06/20 Piper Sandler
Immunic catalyst runway provides share growth opportunities, says Piper Sandler
11/02/20 Piper Sandler
Immunic COVID-19 data could be 'compelling catalyst,' says Piper Sandler
10/02/20 SVB Leerink
Immunic initiated with an Outperform at SVB Leerink
10/02/20 SVB Leerink
Immunic initiated with an Outperform at SVB Leerink
IMUX Immunic
$19.96 /

+1.14 (+6.06%)

  • 05
    Aug
  • 10
    Jun
IMUX Immunic
$19.96 /

+1.14 (+6.06%)

Conference/Events
Immunic management to meet virtually with Mizuho » 12:19
11/23/20
11/23
12:19
11/23/20
12:19
IMUX

Immunic

$20.77 /

+1.95 (+10.36%)

Virtual Meeting to be…

Virtual Meeting to be held on November 24 hosted by Mizuho.

ShowHide Related Items >><<
IMUX Immunic
$20.77 /

+1.95 (+10.36%)

IMUX Immunic
$20.77 /

+1.95 (+10.36%)

11/06/20 Piper Sandler
Immunic catalyst runway provides share growth opportunities, says Piper Sandler
11/02/20 Piper Sandler
Immunic COVID-19 data could be 'compelling catalyst,' says Piper Sandler
10/02/20 SVB Leerink
Immunic initiated with an Outperform at SVB Leerink
10/02/20 SVB Leerink
Immunic initiated with an Outperform at SVB Leerink
IMUX Immunic
$20.77 /

+1.95 (+10.36%)

  • 05
    Aug
  • 10
    Jun
IMUX Immunic
$20.77 /

+1.95 (+10.36%)

Conference/Events
RedHill Biopharma management to meet virtually with BTIG » 11:22
11/23/20
11/23
11:22
11/23/20
11:22
RDHL

RedHill Biopharma

$8.89 /

-0.11 (-1.22%)

Virtual Meeting to be…

Virtual Meeting to be held on November 23 hosted by BTIG.

ShowHide Related Items >><<
RDHL RedHill Biopharma
$8.89 /

-0.11 (-1.22%)

RDHL RedHill Biopharma
$8.89 /

-0.11 (-1.22%)

11/12/20 Roth Capital
RedHill Biopharma price target lowered to $12 from $16 at Roth Capital
09/11/20 BTIG
RedHill Biopharma initiated with a Buy at BTIG
08/14/20 Roth Capital
Roth Capital maintains Buy on RedHill after 'noisy' quarter
07/07/20 SMBC Nikko
RedHill Biopharma initiated with an Outperform at SMBC Nikko
RDHL RedHill Biopharma
$8.89 /

-0.11 (-1.22%)

RDHL RedHill Biopharma
$8.89 /

-0.11 (-1.22%)

Conference/Events
Cantor Fitzgerald biopharma analysts to hold analyst/industry conference call » 10:25
11/23/20
11/23
10:25
11/23/20
10:25
GILD

Gilead

$59.85 /

-0.25 (-0.42%)

, LLY

Eli Lilly

$143.43 /

-2.21 (-1.52%)

, REGN

Regeneron

$521.45 /

+1.88 (+0.36%)

, HGEN

Humanigen

$8.72 /

-0.15 (-1.69%)

Biopharmaceuticals…

Biopharmaceuticals Analysts Chen & Kim and Biotechnology Analyst Young, along with Gerald Pier, PhD, Professor of Medicine, Microbiology & Immunology at Harvard Medical School, discuss Monoclonal Antibodies to treat COVID-19 on an Analyst/Industry conference call to be held on November 23 at 11 am.

ShowHide Related Items >><<
REGN Regeneron
$521.45 /

+1.88 (+0.36%)

LLY Eli Lilly
$143.43 /

-2.21 (-1.52%)

HGEN Humanigen
$8.72 /

-0.15 (-1.69%)

GILD Gilead
$59.85 /

-0.25 (-0.42%)

GILD Gilead
$59.85 /

-0.25 (-0.42%)

11/20/20 Raymond James
Use of Gilead's remdesivir likely to skew to U.S. into Q1, says Raymond James
11/03/20
Fly Intel: Top five analyst initiations
11/03/20 Morgan Stanley
Gilead resumed with an Equal Weight at Morgan Stanley
10/29/20 BMO Capital
Gilead price target lowered to $64 from $74 at BMO Capital
LLY Eli Lilly
$143.43 /

-2.21 (-1.52%)

11/20/20 Stifel
Precision BioSciences price target raised to $22 from $21 at Stifel
11/17/20 Mizuho
Eli Lilly price target lowered to $156 from $164 at Mizuho
11/10/20 Bernstein
Eli Lilly initiated with a Market Perform, $150 price target at Bernstein
11/10/20 Bernstein
Eli Lilly initiated with a Market Perform at Bernstein
REGN Regeneron
$521.45 /

+1.88 (+0.36%)

11/23/20 Piper Sandler
Regeneron Covid cocktail could be meaningful to earnings, says Piper Sandler
11/11/20 Truist
Opthea initiated with a Buy at Truist
11/10/20 SVB Leerink
Regeneron price target lowered to $643 from $653 at SVB Leerink
11/06/20 Truist
Regeneron price target raised to $770 from $750 at Truist
HGEN Humanigen
$8.72 /

-0.15 (-1.69%)

11/06/20 H.C. Wainwright
Humanigen price target raised to $34 from $31 at H.C. Wainwright
10/21/20
Fly Intel: Top five analyst initiations
10/21/20 Cantor Fitzgerald
Humanigen initiated with an Overweight at Cantor Fitzgerald
10/20/20 Cantor Fitzgerald
Humanigen initiated with an Overweight at Cantor Fitzgerald
REGN Regeneron
$521.45 /

+1.88 (+0.36%)

LLY Eli Lilly
$143.43 /

-2.21 (-1.52%)

HGEN Humanigen
$8.72 /

-0.15 (-1.69%)

GILD Gilead
$59.85 /

-0.25 (-0.42%)

  • 18
    Sep
  • 27
    May
REGN Regeneron
$521.45 /

+1.88 (+0.36%)

LLY Eli Lilly
$143.43 /

-2.21 (-1.52%)

GILD Gilead
$59.85 /

-0.25 (-0.42%)

REGN Regeneron
$521.45 /

+1.88 (+0.36%)

LLY Eli Lilly
$143.43 /

-2.21 (-1.52%)

HGEN Humanigen
$8.72 /

-0.15 (-1.69%)

GILD Gilead
$59.85 /

-0.25 (-0.42%)

REGN Regeneron
$521.45 /

+1.88 (+0.36%)

LLY Eli Lilly
$143.43 /

-2.21 (-1.52%)

HGEN Humanigen
$8.72 /

-0.15 (-1.69%)

GILD Gilead
$59.85 /

-0.25 (-0.42%)

Recommendations
Durect positioned for 'market dominance' in alcoholic hepatitis, says Chardan » 08:41
11/23/20
11/23
08:41
11/23/20
08:41
DRRX

Durect

$1.71 /

-0.01 (-0.58%)

Chardan analyst Michael…

Chardan analyst Michael Morabito says Durect's call with Cheif Medical Officer Norman Sussman reaffirmed his conviction in both the likelihood of success for DUR-928 in alcoholic-associated hepatitis and expectations for "market dominance" upon commercial approval. Sussman said that upon seeing the initial Phase IIa results for DUR-928, he believed that most patients hospitalized with alcoholic-associated hepatitis are likely to receive DUR-928 as a therapy upon commercialization, Morabito tells investors in a research note. The analyst views DUR-928's opportunity in alcoholic-associated hepatitis as vast given the significant unmet patient need. He keeps a Buy rating on Durect with a $7 price target, believing DUR-928 should be able to achieve over $1B in revenue upon approval, even on a probability-adjusted basis.

ShowHide Related Items >><<
DRRX Durect
$1.71 /

-0.01 (-0.58%)

DRRX Durect
$1.71 /

-0.01 (-0.58%)

11/03/20 Chardan
Durect Covid trial update increased interest in program, says Chardan
10/30/20
Fly Intel: Top five analyst initiations
10/30/20 Chardan
Durect initiated with a Buy at Chardan
10/20/20 Cantor Fitzgerald
Durect assumed with an Overweight at Cantor Fitzgerald
DRRX Durect
$1.71 /

-0.01 (-0.58%)

DRRX Durect
$1.71 /

-0.01 (-0.58%)

DRRX Durect
$1.71 /

-0.01 (-0.58%)

Recommendations
Apellis price target raised to $67 from $53 at Citi » 06:19
11/23/20
11/23
06:19
11/23/20
06:19
APLS

Apellis

/

+

Citi analyst Yigal…

Citi analyst Yigal Nochomovitz raised the firm's price target on Apellis Pharmaceuticals to $67 from $53 and keeps a Buy rating on the shares. The deal with Sobi offers "meaningful validation" for pegcetacoplan in paroxysmal nocturnal hemoglobinuria and several other systemic indications, Nochomovitz tells investors in a research note.

ShowHide Related Items >><<
APLS Apellis
/

+

APLS Apellis
/

+

11/19/20 Needham
Apellis initiated with a Buy at Needham
09/01/20
Fly Intel: Top five analyst initiations
08/31/20 Stifel
Apellis initiated with a Buy at Stifel
07/20/20 Roth Capital
Apellis initiated with a Buy at Roth Capital
APLS Apellis
/

+

  • 09
    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.